The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial.

F1000Research
Rana M ElDashNagwa Ali Sabri

Abstract

Background: Empagliflozin is an SGLT2 inhibitor approved for use in patients with diabetes mellitus type 2 (DMT2) with or without other cardiovascular disease. Empagliflozin is taken once daily without rationale on the optimal timing for administration. This study aimed to determine the chronopharmacological effects of morning vs evening administration of empagliflozin (10 mg) in healthy Egyptian adults, by investigating the pharmacokinetics and pharmacodynamics parameters of empagliflozin depending on the intake time. Methods: An open label, sequential, two-way crossover trial comprised of two periods with a washout period of 7 days. All participants received a single oral dose of empagliflozin (JARDIANCE ®; 10 mg film coated tablet) in the evening, and after a seven-day washout period, the morning. Pharmacokinetics parameters (primary endpoints: t max (h), C max (ng/ml), AUC 0-t (ng.h/ml); secondary endpoints: AUC 0 to ∞(ng.h/ml)) were assessed. Method validation was done prior to injection in LC/MS/MS and samples were processed by Liquid-Liquid extraction. The pharmacodynamic profile (UGE 0-24) was determined after method validation (glucose hexokinase method). Results: T max increased by 35% in the evening phase compared to...Continue Reading

References

Jul 11, 2013·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Tim HeiseKlaus Dugi
Feb 12, 2014·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Grégoire WuerznerOlivier Bonny
Jun 5, 2015·Food Chemistry·A L GalantJ D Wilson
Sep 18, 2015·American Journal of Physiology. Renal Physiology·Kristen SolocinskiMichelle L Gumz
Jan 29, 2016·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Yui TakeshigeAkira Nishiyama
Jul 22, 2016·Diabetes Care·Paola FiorettoRoberto Vettor
Jan 24, 2018·Free Radical Biology & Medicine·Jermaine G Johnston, David M Pollock
Feb 8, 2018·Physiology·Naureen Javeed, Aleksey V Matveyenko
Aug 26, 2018·Nature Reviews. Nephrology·Dmitri Firsov, Olivier Bonny
Oct 17, 2018·International Urology and Nephrology·Lucas De Lavallaz, Carlos G Musso
Jun 7, 2019·Current Diabetes Reports·Olanrewaju A OlaoyeMichelle L Gumz
Aug 31, 2019·Obesity Research & Clinical Practice·Hiroki YoshiokaMasae Yoshikawa
Jan 28, 2021·The New England Journal of Medicine·Milton Packer, Faiez Zannad

❮ Previous
Next ❯

Software Mentioned

SAS
[UNK]
Dryad

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

© 2021 Meta ULC. All rights reserved